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 SUMMARY 
In countries maintaining national hepatitis C virus (HCV) surveillance systems, a substantial 
proportion of individuals report no risk factors for infection. Our goal was to estimate the 
proportion of diagnosed HCV antibody-positive persons in Scotland (1991–2010) who likely 
acquired infection through injecting drug use (IDU), by combining data on IDU risk from four 
linked data sources using log-linear capture-recapture methods. Of 25521 HCV-diagnosed 
individuals, 14836 (58%) reported IDU risk with their HCV diagnosis. Log-linear modeling 
estimated a further 2,484 HCV-diagnosed individuals with IDU risk, giving an estimated 
prevalence of 83 (95% CI: 81-87%). Stratified analyses indicated variation across birth cohort, 
with estimated prevalence as low as 49% in persons born before 1960 and greater than 90% in 
those born since 1960. These findings provide public-health professionals with a more complete 
profile of Scotland’s HCV-infected population in terms of transmission route, which is essential 






Injecting drug use (IDU) represents the most common risk factor for HCV infection throughout 
the industrialized world.[1] However, a substantial proportion of persons who test HCV 
antibody-positive report no risk factors for acquiring infection. In the United States, 30% of 
persons with acute HCV during 1991–1995 denied a specific exposure associated with becoming 
infected during the six months preceding illness onset, although over half of these reported a 
history of drug use.[2] In England and Wales, 71% (35598/49819) of confirmed HCV infections 
during 1992-2004 lacked risk factor information.[3] Sentinel surveillance of acute HCV infection 
in the United States indicates sexual risk behaviour as a probable route of infection in a 
significant minority of cases [4,5]. Either the potential risk factors for HCV acquisition were not 
carefully elicited in these studies, or there was a significant undefined source of viral 
transmission. A study in the United States showed that the route of HCV acquisition could be 
delineated in 88% of HCV chronically infected patients using a systematic interview approach; 
in nearly all cases, the initially unreported risk factor for HCV transmission was a remote history 
of injecting drug use.[6]  
Deriving an estimate of the percentage of HCV-diagnosed persons with IDU risk from the 
observed data can be problematic (i.e., subject to bias) if there is a large amount of missing risk 
information, which is the case for the national HCV diagnosis database held by Health 
Protection Scotland (HPS), a population-wide record of all individuals testing HCV antibody-
positive since testing commenced in 1991. As at the end of 2009, 35% of records lacked data on 
risk factor(s), and of those with risk information, current/former IDU was specified for 89%.[7] 
 An unknown percentage of persons with missing risk data will have acquired their infection 
through IDU. 
In the current study, we combined data on injecting drug use history available from four other 
data sources – HIV testing, hospital discharges, deaths, treatment for drugs misuse – with that 
on the HCV diagnoses database, using record-linkage methods to identify individuals observed 
across sources. The total number of HCV-diagnosed persons with IDU risk was then estimated 
using capture-recapture statistical methods,[8] originally developed for counting animal 
populations.  Thus, the purpose of our study was to estimate of the proportion of HCV 
antibody-positive and diagnosed persons who were likely to have acquired their infection 
through injecting drug use, which will provide public health policy-makers with a more 
accurate demographic picture of Scotland’s HCV-infected population, and will consequently 
inform on resource allocation for prevention, treatment and care.  
 
METHODS 
The IDU status of HCV-diagnosed persons was sourced from five databases (i.e. HCV 
diagnoses, HIV tests, treatment for drug misuse, hospital discharges, and deaths databases). 
Data on opiate use rather than injecting drug use per se was available from the latter two 
databases, and served as a proxy indicator for IDU.  
The HCV Diagnosis database, maintained by HPS, records all persons who have been 
diagnosed HCV positive (defined as laboratory detection of HCV antibody or a positive PCR 
test result) in Scotland since testing began in 1991. The database contains the following non-
 named information: surname Soundex code (multiple surnames possible; for instance, following 
marriage), forename initial, date of birth, sex, postcode district of residence, hospital/clinic 
number (generated from GUM clinic/hospital referrals only), and data concerning risk activities; 
as at 31 December 2009, this database contained records for 27183 persons. 
The second data source used was the national HIV test database, also held by HPS. It records all 
HIV tests conducted within Scotland, excluding routine screening (e.g., antenatal, renal, 
travel/insurance), and persons under 15 years of age. Data is provided by all NHS laboratories in 
Scotland that perform HIV testing. Individual records on this database contain the following 
non-named information: sex, date of birth, surname and forename initials, health board of 
residence (HB; NHS Scotland administrative area) and a hospital/clinic number generated from 
GUM clinic/hospital referrals only, as well as data concerning risk activities. HIV Test records 
were mapped to distinct individuals using a deterministic approach (i.e., the procedure required 
a complete match on either the set of identifiers sex, date of birth, and initials, or the set of sex, 
date of birth, and hospital/clinic number). The HIV Test database contained records for 523251 
HIV tests conducted between 1 January 1988 and 31 December 2009 (including the testing of 
some stored sera back to 1980). Internal linkage resulted in records for 412994 distinct HIV-
tested individuals. Linkage between the HCV Diagnosis and HIV Test databases was also 
performed in-house at HPS using deterministic methods (i.e., a complete match was required on 
the identifier set (i) sex, date of birth, and initials; or, if initials were missing, the set (ii) sex, date 
of birth, and hospital/clinic number). 
The Scottish Morbidity Records (SMR01) is an episode-based patient record of all acute 
inpatient and day case hospital discharges from non-obstetric, non-psychiatric specialities. 
Information Services Division (ISD) routinely combines SMR01 data with death registrations 
 held by the General Register Office for Scotland to form a linked dataset; the identifiers sex, date 
of birth, initials, and surname Soundex were available. We treated this linked dataset (of 
hospital and death records) as a single data source for the capture-recapture analysis. Linkage of 
records between the HCV Diagnosis database and the hospitalisation/deaths dataset was carried 
out by ISD using probabilistic record-linkage techniques, [9] which allow for matches using 
incomplete identifiers. All hospital and death records (for the period 1 January 1981 to 31 
December 2009) that had linked to HCV diagnosed persons were provided for analysis.  
The final data source used was the Scottish Drug Misuse Database (SDMD), also held by ISD. 
The SDMD is a record of current/former drug users in contact with drug treatment and support 
services, including general practitioners, hospitals, specialist drug clinics, and non-statutory 
agencies. These agencies report information on new contacts (defined as first presentation or 
repeat presentation if it has been at least six months since last attendance) to the SDMD. The 
SDMD contains limited identifying information: sex, date of birth, forename initial, first and 
fourth letter of surname, and postcode sector of residence. Data were available from 1 April 1996 
through 31 December 2009, containing 76364 records representing 28601 distinct individuals. 
Data-linkage between the SDMD and HCV Diagnosis databases was performed by ISD using 
probabilistic methods. 
After exclusion of 1568 persons with insufficient identifiers (defined as missing date of birth and 
two of: sex, initials, surname Soundex), 25615 records on the HCV Diagnosis database were 
available for linkage to the other databases. Approval for this linkage exercise was provided by 
the NHS National Services Scotland Privacy Advisory Committee. The study population was 
further restricted to all records with non-missing sex data, leaving 25521 for analysis. 
 Definition of IDU risk  
An individual on the HCV Diagnosis or HIV Test databases was considered to have IDU risk if 
IDU was listed as a risk factor for acquiring infection. 
In the SMR01/death registrations linked dataset, both hospital discharge diagnosis and cause of 
death codes use the International Classification of Diseases (ICD) Ninth Revision for events 
occurring before 2000, and the Tenth Revision for the period 2000–2009.  IDU risk was inferred if 
the discharge/death record contained a code for opiate use, i.e. any of the ICD-9 codes 304.0 
'Opioid type dependence' or 304.7 'Combinations of opioid type drug with any other drug 
dependence', or the ICD-10 codes F11.0–F11.9 'Mental & behavioural disorders due to use of 
opioids'. 
IDU risk for an individual on the SDMD was defined according to self-report: if at any 
attendance at drug services the client reported having either 'injected in the previous month' or 
'injected in past/not previous month', he/she was classified as having IDU risk.  
Statistical methods 
Log-linear modelling[8] was used to analyse the overlap in the number of HCV-diagnosed 
persons with IDU risk among the four data-sources (HCV diagnosis, HIV test, hospital/death 
and SDMD) and estimate the total population size (i.e., the number of HCV diagnosed IDUs 
including those who are unknown). Backwards stepwise regression was used to find a model 
which adequately described the data with the least number of parameters; 2-way and 3-way 
interaction terms were removed from the model specification if the Akaike Information 
Criterion (AIC) difference was <2 compared with the model including the interaction term. 
 Confidence intervals were determined using the profile likelihood. Model fitting was done using 
the Rcapture package [10] for R statistical software.[11] 
Stratified log-linear analyses were conducted according to four covariates: sex, birth cohort 
(<1960, 1960-1969, 1970-1979, 1980+), health board of residence (Greater Glasgow & Clyde, and 
all other), and calendar year period of HCV diagnosis (<1995, 1995-99, 2000-04, 2005-09). 
Additional analyses were conducted restricting to those HCV-diagnosed who had non-IDU risk 
and to those for whom risk activity leading to infection was unknown. In order to investigate the 
possibility that there might not have been sufficient time for those persons diagnosed with HCV 
near the end of the study period to be ‘captured’ on the other data sources, in a sensitivity 
analysis we restricted the inclusion period to HCV diagnoses made up to 31 December 2006 




Among all HCV-diagnosed persons, 58% (14836/25521) reported IDU risk at the time of their 
HCV diagnosis, 7.3% (1862/25521) reported a non-IDU risk (e.g. blood factor/transfusion) and 
for 35% the risk factor(s) for acquiring infection were unknown. Among those with a reported 
risk(s) on the HCV Diagnosis database, 89% (14836/16698) were current/former IDUs. The 
majority of HCV-diagnosed persons were male (68%), and were born during the 1960s and 1970s 
(70%) (Table 1). 
IDU risk from other data sources 
 Of the 25521 HCV-diagnosed persons, 38%, 49% and 30% were identified as having an IDU risk 
on the HIV test, SDMD and hospital/deaths databases, respectively (Table 1). Among HCV-
diagnosed persons who had reported a non-IDU risk at the time of HCV diagnosis, 11% 
(200/1862), 16% (294/1862) and 9% (171/1862) were identified as having  IDU risk on the HIV 
test, SDMD and hospitalisation/deaths databases, respectively. The distribution of covariates 
across data sources varied somewhat for birth cohort (Table 1). Twenty per cent of all HCV-
diagnosed persons were born prior to the 1960s, compared to only 6% of those identified with 
IDU risk on the SDMD, and 10% of those with IDU risk on either the HCV Diagnosis or 
hospitalisation/deaths data sources. Across data sources, the proportion of individuals with an 
IDU risk residing in Greater Glasgow & Clyde health board was relatively constant, at 40% to 
46%, as was the proportion of males, at 69% to 74%. 
Of the 25521 HCV-diagnosed persons, 18782 (74%) had IDU risk recorded on at least one of the 
four data-sources (i.e. on either the HCV diagnosis, HIV test, SDMD or hospital/deaths 
databases). Overall sensitivity of the HCV Diagnosis database for recording IDU risk (with 
respect to the ‘gold standard’ of IDU status determined from any of the four linked data-
sources) was 79.0%, which varied according to covariate level (Table 1). 
Log-linear modelling 
The log-linear model fitting procedure retained all 2-way and 3-way interaction terms, and 
predicted a further 2484 IDUs not identified from the four data sources (Table 2) for an 
estimated total of 21266 IDUs (95% CI: 20582 3–22140); this corresponded to an estimated IDU 
prevalence among all HCV-diagnosed persons of 83.3% (21266/25521). The sensitivity analysis, 
 in which individuals diagnosed after 31 December 2006 were excluded (resulting n = 20612), 
indicated a slightly higher estimated IDU prevalence (84.8%).  
As a validity check, we also estimated IDU population size for only those persons with IDU risk 
present on the HCV Diagnosis database (n = 14836) from the other three data sources; the 
estimated total number of IDUs was 14336 (95% CI: 14069–14629) and estimated IDU 
prevalence for this group of known IDUs was 96.6%, slightly less than the 100% one would 
expect. However, this analysis was necessarily based on the three data sources with the most 
impoverished IDU risk information. An additional analysis, excluding 1872 persons whose HCV 
diagnosis record specified a non-IDU risk activity (reducing to N = 23659), also resulted in fewer 
estimated HCV-diagnosed IDUs: 19935 (95% CI: 19724–20170) compared with 21266 (the latter 
value estimated in Table 2).  
Stratified log-linear models fitted to the data according to sex, birth cohort, period of HCV 
diagnosis, and HB group indicated substantial variation in estimated IDU prevalence (Table 3). 
Prevalence was lowest for the oldest cohort (born before 1960, 49.4%) and highest for 
individuals born 1970-79 (93.4%). Estimated prevalence was also highest for males (84.6%) and 
for persons diagnosed with HCV during 1995–1999 (91.5%). 
 
DISCUSSION 
This application in Scotland is the first to demonstrate the use of log-linear modelling, based on 
capture-recapture data from four linked sources, to estimate the proportion of IDUs among 
HCV diagnosed persons. The estimated prevalence of current/former IDU was 83% in Scotland’s 
 HCV-diagnosed population, substantially higher than the 58% who had reported IDU as risk 
activity. This estimated prevalence was somewhat lower than an estimate of IDU prevalence 
derived from the 65% of the study population with reported risk factor(s) (89%). However, if 
individuals diagnosed with HCV in the three most recent years of the study period are excluded 
(to allow more opportunity for ‘capture’ by the other data sources), the prevalence was 
estimated at 85%. The latter figure is closely comparable to the value (87%) obtained from 
laboratory surveillance in England & Wales in 1992-2004.[3] 
Stratified analyses indicated that estimated IDU prevalence was lowest (67%) among individuals 
diagnosed with HCV before 1995; this is consistent with an over-representative contribution to 
the early growth of the database from persons with blood clotting disorders. IDU prevalence 
was highest among those born in the 1960s and 1970s, reflecting the age-groups in Scotland in 
which problem drug use is the most prevalent,[12] and in which risky injecting practices are 
frequent.[13] Estimated IDU prevalence was also higher for male, compared with female, HCV 
diagnosed persons (86% and 78%, respectively), which may be due to male sex being an 
independent risk factor for acquiring HCV infection among IDUs, leading to more male than 
female HCV-infected IDUs appearing on the HCV Diagnosis database. 
The estimated sensitivity of the risk information field in the HCV Diagnosis database also varied 
according to birth cohort, and period of diagnosis, with the lowest accuracy observed for the 
youngest cohort (74%) and most recent HCV diagnosis period (69%); the latter finding is 
consistent with there sometimes being a short lag in the collection and recording of risk activity 
data on the HCV Diagnosis database.. 
 The only other study we are aware of in which the number of HCV-infected IDUs was estimated 
using capture-recapture methods was conducted in Porto Alegre, Brazil.[14] In this study, the 
total number of IDUs attending syringe-exchange programmes was estimated based on two 
interviewed samples approximately one month apart, and then overall HCV seroprevalence in 
this population (53%) was assumed for the estimated total IDUs (168/317). However, the 
proportion of IDU risk among HCV-diagnosed persons was not estimated in the study. 
Although the application of capture-recapture and log-linear modelling methods to 
epidemiological questions has certain strengths, it has a number of limitations.  
Firstly, we have had to assume that all four data sources reflect the same (closed) population. In 
reality, especially over the long study period, new individuals enter and others leave the 
population, through initiation of drug use, and death. Secondly, within a given data source, each 
IDU was assumed to have the same chance of being included (i.e., to have the same 
‘catchability’). Although we have attempted to address the issue of heterogeneity in being 
observed within a given data source by conducting stratified analyses, an unknown degree of 
variability will remain. Subgroups with low catchability might bias estimates of the prevalence 
of IDU within the HCV-diagnosed population downwards. Finally, violation of the assumed 
high accuracy of the record-linkage methods could also result in bias. Although the probabilistic 
methods used by ISD to link HCV Diagnosis with the SMR01/deaths linked dataset have 
historically low false positive and false negative rates (<5%[9]), accuracy estimates were not 
available for the other linkages performed. 
In conclusion, the proportion of Scotland’s HCV-diagnosed population who were estimated to 
have acquired their infection through injecting drug use was smaller than if estimated from only 
 the data with non-missing risk information, but once opportunity for capture on the other data 
sources was increased, the proportion with IDU risk was more similar. Information on the route 
by which HCV infection is acquired is essential when targeting risk groups with educational and 
prevention interventions, and is also useful for governmental and public health professionals 
who develop policy and allocate funding for treatment and care. Our results – indicating a 
similar high prevalence of IDU among HCV-diagnosed individuals with missing data on risk 
activities, as among those with risk activity reported – provide evidence that efforts to 
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 Table 1. Study population (first column; n = 25,521) and distribution of IDUs identified via record-linkage 
in each of the four data sources according to sex, birth cohort, health board of residence and calendar year 
period of HCV diagnosis. The sensitivity of IDU status on the HCV Diagnosis database is computed by 
considering the IDUs identified by aggregating all four data sources as the ‘gold standard’. 
 
          All HCV   HCV-diagnosed cases with IDU risk on the following data sources: 
Covariate Diagnosed  (a) HCV Diag    (b) HIV Test  (c) SDMD  (d) SMR01/GROS     Sensitivity 
 N     % N      % N      % N      % N      % % 
 
 
All  25521 – 14836 – 9761 – 12410 – 7625 – 79.0 
 
Sex Female 8177 32.0 4415 29.8 2524 25.9 3806 30.7 2361 31.0 77.5 
 Male 17344 68.0 10421 70.2 7237 74.1 8604 69.3 5264 69.0 79.6 
 
Birth <1960 5168 20.2 1530 10.3 889 9.1 790 6.4 771 10.1 78.1 
cohort 1960-69 8894 34.8 5557 37.5 3637 37.3 4260 34.3 2843 37.3 81.2 
 1970-79 8812 34.5 6119 41.2 4148 42.5 5706 46.0 3170 41.6 78.6 
 1980+ 2647 10.4 1630 11.0 1087 11.1 1654 13.3 841 11.0 74.0 
 
Health GGC 10679 41.8 6743 45.5 4090 41.9 5537 44.6 3045 39.9 82.5 
board Other 14842 58.2 8093 54.5 5671 58.1 6873 55.4 4580 60.1 76.3 
 
Period <1995 2290 9.0 1014 6.8 686 7.0 585 4.7 584 7.7 83.7 
of HCV 1995-99 7163 28.1 4597 31.0 2993 30.7 3388 27.3 2329 30.5 84.3 
diagn. 2000-04 8168 32.0 5341 36.0 3518 36.0 4436 35.7 2642 34.6 82.4 
 2005-09 7900 31.0 3884 26.2 2564 26.3 4001 32.2 2070 27.1 68.9 
Note. HCV Diag refers to the HCV Diagnosis database; SMR01/GROS refers to hospital/deaths data; GGC 
refers to Greater Glasgow & Clyde health board. 
  
 Table 2. IDU risk status of 25,521 individuals diagnosed with HCV in Scotland to 31 Dec 2009, according 
to four data-sources ((A) HCV Diagnosis, (B) HIV Test, (C) combined hospital discharges/deaths, and (D) 
SDMD). 95% confidence intervals were derived using the profile likelihood. 
 












Y Y Y Y 2814 
N Y Y Y    513 
Y N Y Y   1914 
N N Y Y     801 
Y Y N Y  2686 
N Y N Y    520 
Y N N Y    2083 
N N N Y    1079 
Y Y Y N 623 
N Y Y N   126 
Y N Y N   526 
N N Y N   308 
Y Y N N 1880 
N Y N N 599 
Y N N N 2310 
N N N N –  
Total number of HCV-diagnosed persons identified with IDU risk from the four 
data-sources (A) to (D) 
 18,782 
Estimated number of HCV-diagnosed persons with IDU risk from log-linear 
modeling, but were not identified as such from the four data-sources (A) to (D) 
2,484 
Estimated total number of HCV-diagnosed IDUs  




Note. Y = yes; N = no. Backward step-wise fitting of log-linear model (residual deviance of 0 on 0 residual 
df) included main effects for data-sources (A) HCV diagnoses, (B) HIV test, (C) hospital discharge/deaths 
and (D) SDMD, and all 2-way and 3-way interactions between data-sources. 
 Table 3. Results of log-linear modelling and estimated prevalence of IDU in HCV-diagnosed persons, for 
both full and stratified datasets; the latter were stratified by sex, birth cohort and period of HCV 
diagnosis. 95% confidence intervals were derived using the profile likelihood.  
 
 IDU risk, from    IDU risk, total Estimated Saturated 
 N data sources (%)      N         95% CI  prevalence model? 
 
Full dataset  25521 18782 (73.6) 21266 20582-22140 83.3% Y 
 
Stratified analysis 
Sex Female 8177 5694 (69.6) 6230 6130-6341 76.2% Na 
 Male 17344 13088 (75.5) 14669 14235-15229 84.6% Nb 
 
Birth <1960 5168 1958 (37.9) 2554 2366-2801 49.4% Nc 
cohort 1960-69 8894 6841 (76.9) 8089 7575-8865 91.0% Y 
 1970-79 8812 7781 (88.3) 8226 8146-8316 93.4% Nd 
 1980+ 2647 2202 (83.2) 2405 2347-2474 90.8% Ne 
 
Health GG 10679 8174 (76.5) 8856 8698-9045 82.9% Nf 
Board Other 14842 10608 (71.5) 12573 11914-13491 84.7% Y 
 
Period <1995 2290 1211 (52.9) 1411 1304-1600 61.6% Ng 
of HCV 1995-99 7163 5454 (76.1) 6554 6039-7389 91.5% Y 
diag. 2000-04 8168 6479 (79.3) 6912 6830-7004 84.6% Nh 
 2005-09 7900 5638 (71.4) 6192 6075-6326 78.4% Ni  
 
Note. ID’d=Identified; Y=yes; N=no; CI=confidence interval; GG=Greater Glasgow & Clyde. 'Saturated 
model?' = Y refers to a log-linear model in which all main effects and all possible 2- and 3-way interactions 
were retained after applying the backward stepwise selection. a All 2-way interactions only (residual df = 
4, deviance = 2.53); b all 2-way interactions and A:B:D, A:C:D, and B:C:D only (residual df = 1, deviance = 
1.70);  c all 2-way interactions and A:C:D only (residual df = 3, deviance = 1.66); d all 2-way interactions only 
(residual df = 4, deviance = 1.90); e all 2-way interactions except A:C and B:C (residual df = 6, deviance = 
3.47);  f all 2-way interactions and A:B:C and A:C:D only (residual df = 2). g all 2-way interactions and 
A:B:C and A:C:D only (residual df = 2, deviance = 2.33; h all 2-way interactions except B:C (residual df = 5, 
deviance = 5.50); i all 2-way interactions and A:B:C and B:C:D only (residual df = 2, deviance = 0.42). 
A=HCV-Diagnosis, B=HIV-Test, C=SMR01/Deaths, and D=SDMD. 
 
